(Reuters) - U.S. regulators on Friday approved Gilead Sciences Inc's all-oral hepatitis C drug, clearing the way for the company to increase its revenue from sales of treatments for the liver-destroying viral infection. The new drug, to be sold under the brand name Harvoni, combines Gilead's $1,000-per-pill Sovaldi, with another drug, ledipasvir, and eliminates the need for two older treatments that needed to be taken along with Sovaldi. Gilead did not immediately respond to a request for comment on its plans for pricing Harvoni. ... via Health News Headlines - Yahoo News Read More Here..
No comments:
Post a Comment